CELLINK, a leading provider of innovative biomaterials and technologies for 3D bioprinting applications in the life sciences, announced a collaboration with Carcinotech, which focuses on the production of cancer research models for drug testing, cancer drug discovery and the study of cancer biology. This collaboration seeks to use CELLINK’s patent-pending bioinks to help Carcinotech develop its proprietary 3D-bioprinted cancer research model that will mimic cancer systems found in the human body on a micro-size chip.
One of the biggest challenges in cancer drug testing and treatments today is that 85% of drugs in clinical trials fail to reach the market. Clinical trial activity remains a high-risk endeavor as the oncology composite success rate fell to 8% in 2018 from 11.7% in 2017 (Global Oncology Trends 2019, IQVIA). The major reason for this failure rate is the lack of good research and testing models. Animal models currently used for pre-clinical drug testing are not a good representation of human cancer systems, and there has been a 14% reduction in the use of animal models from 2011 as pharmaceutical companies and clinical research organizations (CROs) look for better drug testing models for cancer. Carcinotech hopes to solve this problem with the development of a micro-size chip that mimics cancer systems in the human body. The collaboration will leverage CELLINK’s innovative and patent-pending bioink, Extra Cellular Matrix (ECM) and Laminin based Bioinks, which enable human cells to grow and thrive as they would in the human body.
Dr. Itedale Namro Redwan, CSO, CELLINK
“It is an honor to announce this partnership with Carcinotech. This collaboration will extend the pharmaceutical development segment for CELLINK and advance the tools used for future cancer drug development processes.”
Ishani Malhotra, Managing Director, Carcinotech
“It’s a wonderful opportunity for Carcinotech to collaborate with CELLINK. The expertise and knowledge CELLINK has on bioprinting will help us advance towards commercialization. Our vision is to be at the forefront of accelerating cancer drug testing and discovery through our propriety products and services, and this collaboration will play a great role in fulfilling that vision.”
The developed technology that will be used within the project was partially supported by an H2020-SMEInst-2018-2020-2 grant with project number 829846 from the European Union.
For further information, please contact:
Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
Email: [email protected]
Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
Email: [email protected]
CELLINK is a life-science company developing and delivering life-science solutions for cell culturing, with a focus on three application areas, bioprinting, analysis, and liquid handling and bioprocessing. It develops and markets cell culture technologies, enabling researchers in the life sciences to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with a global reach in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.
Carcinotech is a UK-based company that focuses on the production of 3D bioprinted cancer research models. The products can not only replace animal testing in pre-clinical trials but can also be used as a device for testing personalised medicines and is a good representation of the cancer environment in a human body. Our vision is to have our device at the centre of drug discovery in public and private pharmaceutical laboratories as well as driving innovative research in academic institutions. Despite advances in the field of cancer research, the demand for new therapies is ever growing and we are confident that our devices will be at the forefront of this endeavour. We also support the ethical treatment of animals and strive to develop research devices which will provide alternatives to animal testing. For more information visit www.carcinotech.co.uk.